Patents by Inventor Aslan MANSUROV

Aslan MANSUROV has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220281936
    Abstract: he disclosure relates to the engineering of collagen-binding modification of masked therapeutic agents comprising one or more tumor-associated protease cleavage sites. Upon exposure to tumor-associated proteases in the tumor microenvironment, the polypeptide is cleaved, which unmasks the therapeutic agent, reducing off-target side effects and toxicity associated with systemic administration. Accordingly, aspects of the disclosure relate to a polypeptide comprising a therapeutic agent linked to a masking agent through a linker, wherein the linker comprises one or more tumor-associated protease cleavage sites, and wherein the masking agent blocks the association of the therapeutic agent to its therapeutic target, and further wherein the polypeptide is operatively linked to a collagen binding domain or a tumor-targeting agent.
    Type: Application
    Filed: July 24, 2020
    Publication date: September 8, 2022
    Applicant: The University of Chicago
    Inventors: Jeffrey HUBBELL, Jun ISHIHARA, Juan MENDOZA, Aslan MANSUROV
  • Publication number: 20220118089
    Abstract: The disclosure relates to the engineering of collagen-binding modification of anti-inflammatory agents using collagen-binding peptide (CBP) and vWF A3 to achieve targeted therapy for inflammatory diseases. Accordingly, embodiments of the disclosure relate to a composition comprising an anti-inflammatory agent operatively linked to an extracellular matrix (ECM)-affinity peptide. Also disclosed are cytokines and anti-inflammatory agents, such as CD200, linked to a serum protein and/or an ECM-affinity peptide. Further aspects of the disclosure relate to a method for treating an autoimmune or inflammatory condition in a subject comprising administering a composition of the disclosure to the subject.
    Type: Application
    Filed: February 25, 2020
    Publication date: April 21, 2022
    Applicant: The University of Chicago
    Inventors: Jeffrey A. HUBBELL, Kiyomitsu KATSUMATA, Ako ISHIHARA, Jun ISHIHARA, Aslan MANSUROV
  • Publication number: 20210094995
    Abstract: The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with a cytokine that is specifically targeted to and/or retained intra- or peri-tumorally, limiting systemic exposure and reducing side-effects. Accordingly, aspects of the disclosure relate to a composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide. An ECM-affinity peptide is one that has affinity for an extracellular matrix protein.
    Type: Application
    Filed: March 5, 2019
    Publication date: April 1, 2021
    Inventors: Jeffrey A. HUBBELL, Jun ISHIHARA, Ako ISHIHARA, Koichi SASAKI, Melody SWARTZ, Aslan MANSUROV